<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E3D2D81D-2671-410B-9D1C-BBBBDA8CF466"><gtr:id>E3D2D81D-2671-410B-9D1C-BBBBDA8CF466</gtr:id><gtr:name>Johnson &amp; Johnson Ltd</gtr:name><gtr:address><gtr:line1>Foundation Park</gtr:line1><gtr:line2>Roxborough Way</gtr:line2><gtr:line4>Maidenhead</gtr:line4><gtr:line5>Berkshire</gtr:line5><gtr:postCode>SLG 3UG</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Psychiatry</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E3D2D81D-2671-410B-9D1C-BBBBDA8CF466"><gtr:id>E3D2D81D-2671-410B-9D1C-BBBBDA8CF466</gtr:id><gtr:name>Johnson &amp; Johnson Ltd</gtr:name><gtr:address><gtr:line1>Foundation Park</gtr:line1><gtr:line2>Roxborough Way</gtr:line2><gtr:line4>Maidenhead</gtr:line4><gtr:line5>Berkshire</gtr:line5><gtr:postCode>SLG 3UG</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/382F3EEB-8130-4EB4-9046-EC4190AD6E07"><gtr:id>382F3EEB-8130-4EB4-9046-EC4190AD6E07</gtr:id><gtr:firstName>Philip</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Cowen</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C50EE9C0-A0E3-4EB0-9EFD-C424F4204D12"><gtr:id>C50EE9C0-A0E3-4EB0-9EFD-C424F4204D12</gtr:id><gtr:firstName>Catherine</gtr:firstName><gtr:surname>Harmer</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0701421"><gtr:id>5416DDC4-9469-44B3-9366-29B9EFD88ECA</gtr:id><gtr:title>Clinical Psychopharmacology of 5-HT</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0701421</gtr:grantReference><gtr:abstractText>Clinical depression is a common illness, often beginning in early adulthood, which can recur throughout a lifetime. The recurrent nature of clinical depression, together with the burden it places on patients and their families, makes this condition one of leading medical causes of suffering and disability. Understanding the biochemical changes in the brain in depression will help us devise better treatments and also improve efforts at prevention. A neurotransmitter called serotonin (5-HT) plays an important role in both the causation of depression and in current drug treatments. In this study we will use advances in brain imaging to study how 5-HT acts in the brain to alter mood. For example we will use magnetic resonance spectroscopy (MRS) to see how 5-HT interacts with special neurons in the brain that use a chemical messenger called glutamate. We believe that the interactions between 5 HT and glutamate may be very important in helping us understand the cause of depression and in developing more effective methods of treatment. A major problem in the treatment of depression is the unpredictability of response to current drug treatments; some patients do well, others are not helped very much. We believe that antidepressants which work through 5-HT such as the selective serotonin re-uptake inhibitors (SSRIs) may produce their therapeutic effects by acting on the way the brain analyses emotional information. The use of functional magnetic resonance imaging (fMRI) allows us to examine the brain networks involved in emotional experience. We will use therefore use fMRI to study how these brain networks are influenced by SSRIs in depressed patients and whether the changes we see enable us to predict those patients who will do well with treatment.</gtr:abstractText><gtr:technicalSummary>Abnormalities in brain serotonin (5-HT) function appear to play an important role in the pathophysiology of depression and the therapeutic effects of antidepressant treatment. The present proposal builds on our previous work with ligand positron emission tomography (PET) showing that people at high risk of depression have abnormal expression of 5-HT receptors on cortical and limbic neurones. We believe that the abnormal expression of 5-HT receptors on prefrontal glutamatergic neurones leads to excessive glutamatergic feedback on 5-HT cells in the dorsal raphe, an idea we shall test using ligand PET to measure 5-HT release in this brain region. Animal experimental studies suggest that the effects of ascending 5-HT pathways on mood in depressed patients are mediated via critical interactions with glutamatergic neurones, an idea we shall translate to human studies using developments in proton magnetic resonance spectroscopy (MRS) to measure glutamate concentrations in medial prefrontal cortex in response to 5-HT manipulation. We will also assess whether effects of the NMDA receptor antagonist, ketamine, on cortical glutamate are linked to its reported antidepressant action in patients unresponsive to conventional treatments. At a neuropsychological level we believe that the effects of 5-HT on mood are exerted via modulatory actions on the neural circuitry supporting emotional experience and regulation. We will therefore use functional magnetic resonance imaging (fMRI) to test the hypothesis that the therapeutic effects of selective serotonin re-uptake inhibitors (SSRIs) in depressed patients are mediated by early positive changes in the neural processing of emotional information.</gtr:technicalSummary><gtr:fund><gtr:end>2013-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1625737</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Nuffield Department of Medicine</gtr:department><gtr:description>Oxford Biomedical Research Centre</gtr:description><gtr:id>E36E9A43-1EB8-44F2-91D6-344E0B2BADFB</gtr:id><gtr:impact>papers submitted fro publication</gtr:impact><gtr:outcomeId>HbYPDHG5cXE-1</gtr:outcomeId><gtr:partnerContribution>provision of patients and immunological expertise</gtr:partnerContribution><gtr:piContribution>Study of the effect of interferon alpha on brain neurochemistry using MRS</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Johnson &amp; Johnson</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Neuroscience Johnson and Johnson</gtr:department><gtr:description>Bupropion study</gtr:description><gtr:id>7F32394B-66EC-479E-8F40-2427DFF1FCD6</gtr:id><gtr:impact>Collaboration on planned study in depressed patients</gtr:impact><gtr:outcomeId>Je4y2AHKTv5-1</gtr:outcomeId><gtr:partnerContribution>Financial contribution for the study</gtr:partnerContribution><gtr:piContribution>Models for assessment of dopamine function in emotional processing and reward</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Psychology</gtr:department><gtr:description>Wellcome Trust Inflammation Collaboration</gtr:description><gtr:id>13AE7640-DF76-46A5-8C21-81A04384BF4D</gtr:id><gtr:impact>Application for funding to Wellcome Trust- Funded approved in Sept 2014</gtr:impact><gtr:outcomeId>p2xVsHjXPdF-1</gtr:outcomeId><gtr:partnerContribution>Expertise in immunophenotyping; access to novel therapeutic compounds</gtr:partnerContribution><gtr:piContribution>Part of a large collaboration with academe and Industry to identify the role of inflammation in depression. Our contribution is to identify the most suitable group of depressed patients and to provide patients and samples for the collaboration</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Pharmacology</gtr:department><gtr:description>Pharmacology</gtr:description><gtr:id>8A24E648-5DEB-42BA-868E-73CF810143B3</gtr:id><gtr:impact>Scientific knowledge and translational studies. Possible patent</gtr:impact><gtr:outcomeId>56d6df6aa0c241.04635060-1</gtr:outcomeId><gtr:partnerContribution>Studies in animals to act as a platform for human work</gtr:partnerContribution><gtr:piContribution>MRC developmental pathway funding for ebselen in the treatment of impulsivity</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Pharmacology</gtr:department><gtr:description>Pharmacology</gtr:description><gtr:id>891E63AE-357B-4404-8A96-BE2302744503</gtr:id><gtr:impact>Grant from BBSRC</gtr:impact><gtr:outcomeId>ANL4rSnEEmU-1</gtr:outcomeId><gtr:partnerContribution>basic animal studies which act as platform for human work.</gtr:partnerContribution><gtr:piContribution>Collaboration on clinical translation of a lithium-mimetic</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Newspaper interviews and reports</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A5ED5F87-86AA-4C7E-84A9-2F4EBAC07FE4</gtr:id><gtr:impact>Catherine Harmer gave interviews to newspapers about her work on emotional processing and antidepressants

Further articles in the press</gtr:impact><gtr:outcomeId>1C1498E2FFE</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Autumn psychiatry school</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>764A6170-8799-4E74-A231-903FEF97D64A</gtr:id><gtr:impact>40 medical students and junior doctors attended a series of lectures and visits to our department

Increased interest in a career in psychiatry in students and junior doctors which will hopefully lead to better recruitment rates to the speciality.</gtr:impact><gtr:outcomeId>sNpVoB85A3E</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:url>http://www.psych.ox.ac.uk</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cheltenham Science Festival</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>846671F8-4865-40D8-8CED-9582219DAA38</gtr:id><gtr:impact>200 people attended talk on antidepressants by Catherine Harmer. Led to intense audience discussion and newspaper articles.

Newspaper articles and journalists contacting the lab</gtr:impact><gtr:outcomeId>aP4vexxYEgV</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visit Oxford</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>F6EAD511-2165-4A8E-9C29-CD7890CAEA26</gtr:id><gtr:impact>Attending schools to talk about biological research in mental health

Requests for work placements</gtr:impact><gtr:outcomeId>C3C54CAB5F9</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2006,2007</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1700000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Programme Grant</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>6BDD05CB-A45B-4017-B8B9-70056C9E4B98</gtr:id><gtr:outcomeId>guihyUcJf8A</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Research Grant</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>F2254872-911B-47D3-A7D4-90234643F50D</gtr:id><gtr:outcomeId>EDE133F57AC0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>650000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Johnson and Johnson pre-competitive award</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Johnson &amp; Johnson</gtr:fundingOrg><gtr:id>6AE89DA3-AFAA-4B52-B5B1-966D012EFD7B</gtr:id><gtr:outcomeId>CZuwWT1jaBY</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2013-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1113147</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Biomedical catalyst</gtr:description><gtr:end>2019-01-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>97A9EFF4-7322-4F69-81C3-92CAEDCA9890</gtr:id><gtr:outcomeId>56d6e57f3597d6.25221012</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>A psychological test battery for the detection of psychotropically active drugs</gtr:description><gtr:grantRef>G0701421</gtr:grantRef><gtr:id>C3BA2EF3-7E01-4A33-8F26-15FEFC41BBFF</gtr:id><gtr:impact>Industrial support including funding</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>QzxeJVhXYos</gtr:outcomeId><gtr:protection>Copyrighted (e.g. software)</gtr:protection><gtr:title>Emotional Test Battery</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>NMHB</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>972F354D-50E2-4325-98B5-DD34173C3C10</gtr:id><gtr:outcomeId>gnLHx9HFNR4</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>MRC strategic review on Mental Health Research</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>41C5302D-51F0-47C6-B941-6FC0ACF63F5B</gtr:id><gtr:outcomeId>DD500CCEC28</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>BAP guideline on depression</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8EBDBF84-B0AE-4734-8674-910D8F5339DB</gtr:id><gtr:impact>Improvement in the pharmacological management of depression</gtr:impact><gtr:outcomeId>Pq3vEe56M8g</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>NICE Panel on GAD</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>57068366-E175-415F-972B-1B84E4DDD790</gtr:id><gtr:impact>An evidence-based guideline on the treatment of generalised anxiety disorder. Improvements in clinical practice and management.</gtr:impact><gtr:outcomeId>Wx3mMsTKQV1</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>Antioxidant drug repurposed as lithium mimetic</gtr:description><gtr:id>CE5AA220-6147-4573-99FB-C6A293DFA613</gtr:id><gtr:impact>Principle of drug repurposing for psychiatry. basic to clinical collaboration. New drug development for area of great unmet clinical need.</gtr:impact><gtr:outcomeId>qCwsBe2w1E9</gtr:outcomeId><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Ebselen</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>New developments in MRS analysis</gtr:description><gtr:id>5AC7336B-7906-423E-8B05-226E7EF72221</gtr:id><gtr:impact>Papers in high impact journals. Further research funding</gtr:impact><gtr:outcomeId>TG36NDiSSCH</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>MRS development</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>P1Vital</gtr:companyName><gtr:description>Interface between Oxford University Dept of Psychiatry and Pharmaceutical Industry. Applying novel methods of drug discovery to screen for new antidperessants at phase 1-2; http://www.p1vital.com/</gtr:description><gtr:id>8FBE33BF-112C-486B-A2E6-6344A7DC58A4</gtr:id><gtr:impact>Income generation from Industry through take up of screening studies</gtr:impact><gtr:outcomeId>B76828EA966</gtr:outcomeId><gtr:url>http://www.p1vital.com</gtr:url><gtr:yearCompanyFormed>2006</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>04875885-0AE5-497E-BCE1-FA9064777493</gtr:id><gtr:title>SSRI administration reduces resting state functional connectivity in dorso-medial prefrontal cortex.</gtr:title><gtr:parentPublicationTitle>Molecular psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4319dfcd8ef4be50b24fbceb03f6bfac"><gtr:id>4319dfcd8ef4be50b24fbceb03f6bfac</gtr:id><gtr:otherNames>McCabe C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1359-4184</gtr:issn><gtr:outcomeId>pm_13634_24_21263442</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CDBF327D-0924-4970-9483-7B16C66EA394</gtr:id><gtr:title>NK1 receptor antagonism and emotional processing in healthy volunteers.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f2d5c7b9698c9414404e8f93f736b37c"><gtr:id>f2d5c7b9698c9414404e8f93f736b37c</gtr:id><gtr:otherNames>Chandra P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>D3806EDE7B1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2F70BAD4-2046-496C-A4B7-CDCE1FF59F23</gtr:id><gtr:title>Effect of a single dose of citalopram on amygdala response to emotional faces.</gtr:title><gtr:parentPublicationTitle>The British journal of psychiatry : the journal of mental science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4c2a8c889869049188f716ea80809693"><gtr:id>4c2a8c889869049188f716ea80809693</gtr:id><gtr:otherNames>Murphy SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-1250</gtr:issn><gtr:outcomeId>6077853A630</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1B1E9E14-C8DE-4A24-972A-635BD2EAF365</gtr:id><gtr:title>NK1 receptor antagonism and the neural processing of emotional information in healthy volunteers.</gtr:title><gtr:parentPublicationTitle>The international journal of neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4319dfcd8ef4be50b24fbceb03f6bfac"><gtr:id>4319dfcd8ef4be50b24fbceb03f6bfac</gtr:id><gtr:otherNames>McCabe C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1461-1457</gtr:issn><gtr:outcomeId>8C77C517F7B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5CE1715A-D3C7-4D11-B128-DB639280689D</gtr:id><gtr:title>Negative ion treatment increases positive emotional processing in seasonal affective disorder.</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9714622cbdf3aade07f0e4b795152598"><gtr:id>9714622cbdf3aade07f0e4b795152598</gtr:id><gtr:otherNames>Harmer CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn><gtr:outcomeId>pm_13634_24_22152099</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B92A343F-823E-4114-B3AA-3A1E5C15573A</gtr:id><gtr:title>Early increase in marker of neuronal integrity with antidepressant treatment of major depression: 1H-magnetic resonance spectroscopy of N-acetyl-aspartate.</gtr:title><gtr:parentPublicationTitle>The international journal of neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/880cf52474bd701e7fe0e2f26464865f"><gtr:id>880cf52474bd701e7fe0e2f26464865f</gtr:id><gtr:otherNames>Taylor MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1461-1457</gtr:issn><gtr:outcomeId>pm_13634_24_22449253</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F1EFC754-105E-4DA1-B82F-9F511CFEBA64</gtr:id><gtr:title>Early changes in emotional processing as a marker of clinical response to SSRI treatment in depression.</gtr:title><gtr:parentPublicationTitle>Translational psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08d88219fbc18330d20e7155a934dbb5"><gtr:id>08d88219fbc18330d20e7155a934dbb5</gtr:id><gtr:otherNames>Godlewska BR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2158-3188</gtr:issn><gtr:outcomeId>58ad93484b44c2.77164013</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DF77B9AC-0B9F-4147-B4BB-8BC60E857385</gtr:id><gtr:title>What has serotonin to do with depression?</gtr:title><gtr:parentPublicationTitle>World psychiatry : official journal of the World Psychiatric Association (WPA)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/657ebacd2810a554a2431b4b880d4b90"><gtr:id>657ebacd2810a554a2431b4b880d4b90</gtr:id><gtr:otherNames>Cowen PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1723-8617</gtr:issn><gtr:outcomeId>56d6c6576ccef1.16907086</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A4C9E49-BD5C-4887-82AA-65659956940D</gtr:id><gtr:title>Short-term SSRI treatment normalises amygdala hyperactivity in depressed patients.</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08d88219fbc18330d20e7155a934dbb5"><gtr:id>08d88219fbc18330d20e7155a934dbb5</gtr:id><gtr:otherNames>Godlewska BR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn><gtr:outcomeId>pm_13634_24_22716999</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>86BD7538-427A-44A5-87C4-7490AC01BF8C</gtr:id><gtr:title>Subcortical brain alterations in major depressive disorder: findings from the ENIGMA Major Depressive Disorder working group.</gtr:title><gtr:parentPublicationTitle>Molecular psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e72cfe9cae3a7cf9e277bc23c7bfbe49"><gtr:id>e72cfe9cae3a7cf9e277bc23c7bfbe49</gtr:id><gtr:otherNames>Schmaal L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1359-4184</gtr:issn><gtr:outcomeId>5a8add6e133b04.77387958</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FB5362ED-4AF5-4F1A-8A42-EF3A6C850C7C</gtr:id><gtr:title>The D2 antagonist sulpiride modulates the neural processing of both rewarding and aversive stimuli in healthy volunteers.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4319dfcd8ef4be50b24fbceb03f6bfac"><gtr:id>4319dfcd8ef4be50b24fbceb03f6bfac</gtr:id><gtr:otherNames>McCabe C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>HkjHSMNCqyP</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3FF63443-170F-4C7A-BDB8-9A9D90499C83</gtr:id><gtr:title>When less is more: a functional magnetic resonance imaging study of verbal working memory in remitted depressed patients.</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66e098825713ff2a824ed36b33d241e9"><gtr:id>66e098825713ff2a824ed36b33d241e9</gtr:id><gtr:otherNames>Norbury R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn><gtr:outcomeId>pm_13634_24_23867077</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC9B921B-F7B2-4298-8FDC-BAEF9428D6C7</gtr:id><gtr:title>Effect of Citalopram on Emotion Processing in Humans: A Combined 5-HT[C]CUMI-101 PET and Functional MRI Study.</gtr:title><gtr:parentPublicationTitle>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f36a0b46d325daf7d58d5c21cdcf6fda"><gtr:id>f36a0b46d325daf7d58d5c21cdcf6fda</gtr:id><gtr:otherNames>Selvaraj S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0893-133X</gtr:issn><gtr:outcomeId>5a8ac1e599c832.53391853</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>97692F5A-2BD4-4B71-9A6B-DAA9151493B0</gtr:id><gtr:title>5-HT and depression: is the glass half-full?</gtr:title><gtr:parentPublicationTitle>Current opinion in pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/19fa809ab044064917d3ddecde439ea3"><gtr:id>19fa809ab044064917d3ddecde439ea3</gtr:id><gtr:otherNames>Sharp T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1471-4892</gtr:issn><gtr:outcomeId>pm_13634_24_21377932</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F78F609E-671F-4278-A167-E366DA30D3F5</gtr:id><gtr:title>Decreased regional gray matter volume in S' allele carriers of the 5-HTTLPR triallelic polymorphism.</gtr:title><gtr:parentPublicationTitle>Molecular psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f36a0b46d325daf7d58d5c21cdcf6fda"><gtr:id>f36a0b46d325daf7d58d5c21cdcf6fda</gtr:id><gtr:otherNames>Selvaraj S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1359-4184</gtr:issn><gtr:outcomeId>pm_13634_24_21042318</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4BAFB5D9-02C1-48CA-96B6-CEBF0A22BEC9</gtr:id><gtr:title>Classification of depressive disorders.</gtr:title><gtr:parentPublicationTitle>Current topics in behavioral neurosciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/657ebacd2810a554a2431b4b880d4b90"><gtr:id>657ebacd2810a554a2431b4b880d4b90</gtr:id><gtr:otherNames>Cowen PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1866-3370</gtr:issn><gtr:outcomeId>pm_13634_24_22923074</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3ACE3C66-3636-4E37-A531-9837F582F06A</gtr:id><gtr:title>Simplified quantification of 5-HT2A receptors in the human brain with [11C]MDL 100,907 PET and non-invasive kinetic analyses.</gtr:title><gtr:parentPublicationTitle>NeuroImage</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/790beb2221948cfae2d3f4d94715a8aa"><gtr:id>790beb2221948cfae2d3f4d94715a8aa</gtr:id><gtr:otherNames>Meyer PT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1053-8119</gtr:issn><gtr:outcomeId>56d6c35a6f9d81.11402220</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A388A7E5-196E-4213-A4C2-49826FBFA762</gtr:id><gtr:title>Memory impairment in young women at increased risk of depression: influence of cortisol and 5-HTT genotype.</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/883e93881f45f4205fb363e9972ff32e"><gtr:id>883e93881f45f4205fb363e9972ff32e</gtr:id><gtr:otherNames>Mannie ZN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn><gtr:outcomeId>4E10B7510BF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F924D84-BDE2-429C-A0C3-59838C2DA7E8</gtr:id><gtr:title>Diminished brain 5-HT transporter binding in major depression: a positron emission tomography study with [11C]DASB.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f36a0b46d325daf7d58d5c21cdcf6fda"><gtr:id>f36a0b46d325daf7d58d5c21cdcf6fda</gtr:id><gtr:otherNames>Selvaraj S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>3C82A22BAB3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A04C852E-8673-48B4-BA9B-FFA0D04FADFB</gtr:id><gtr:title>'It's the way that you look at it'--a cognitive neuropsychological account of SSRI action in depression.</gtr:title><gtr:parentPublicationTitle>Philosophical transactions of the Royal Society of London. Series B, Biological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9714622cbdf3aade07f0e4b795152598"><gtr:id>9714622cbdf3aade07f0e4b795152598</gtr:id><gtr:otherNames>Harmer CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0962-8436</gtr:issn><gtr:outcomeId>pm_13634_24_23440467</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2C9DE348-5836-4EEC-9D70-5C1D063C27B0</gtr:id><gtr:title>Cortical glutathione levels in young people with bipolar disorder: a pilot study using magnetic resonance spectroscopy.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08d88219fbc18330d20e7155a934dbb5"><gtr:id>08d88219fbc18330d20e7155a934dbb5</gtr:id><gtr:otherNames>Godlewska BR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>56d6c65a83bfa1.81545720</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E00E958D-8FBB-4E48-877C-4B93A9A2CAA9</gtr:id><gtr:title>Lack of effect of ketamine on cortical glutamate and glutamine in healthy volunteers: a proton magnetic resonance spectroscopy study.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/880cf52474bd701e7fe0e2f26464865f"><gtr:id>880cf52474bd701e7fe0e2f26464865f</gtr:id><gtr:otherNames>Taylor MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>pm_13634_24_21616979</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>653D9772-DAE7-4B2B-A725-D576F73CB375</gtr:id><gtr:title>Effect of interferon-a on cortical glutamate in patients with hepatitis C: a proton magnetic resonance spectroscopy study.</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/880cf52474bd701e7fe0e2f26464865f"><gtr:id>880cf52474bd701e7fe0e2f26464865f</gtr:id><gtr:otherNames>Taylor MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn><gtr:outcomeId>545a573f8bee31.54146216</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A765DBFE-3B66-48A9-BEB2-8EE4D4F7EA14</gtr:id><gtr:title>Tianeptine in an experimental medicine model of antidepressant action.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/377ce07d9b305025f968216d5044b1e4"><gtr:id>377ce07d9b305025f968216d5044b1e4</gtr:id><gtr:otherNames>Cooper CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>56d6c6584c8092.58678117</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>27B11916-2665-4BA7-A03F-5EF22B7518A6</gtr:id><gtr:title>Unedited in vivo detection and quantification of ?-aminobutyric acid in the occipital cortex using short-TE MRS at 3 T.</gtr:title><gtr:parentPublicationTitle>NMR in biomedicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/edd8474b99dab84a174df456f80a5901"><gtr:id>edd8474b99dab84a174df456f80a5901</gtr:id><gtr:otherNames>Near J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0952-3480</gtr:issn><gtr:outcomeId>DZSjnTuoNCG</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E4A486C8-0429-48BA-A6EA-D5FBA17E8ED7</gtr:id><gtr:title>Lack of effect of citalopram on magnetic resonance spectroscopy measures of glutamate and glutamine in frontal cortex of healthy volunteers.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/880cf52474bd701e7fe0e2f26464865f"><gtr:id>880cf52474bd701e7fe0e2f26464865f</gtr:id><gtr:otherNames>Taylor MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>1C08DF3A538</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CFB29B1C-72EF-4628-A3CF-29A46C56E960</gtr:id><gtr:title>The role of serotonin in nonnormative risky choice: the effects of tryptophan supplements on the &amp;quot;reflection effect&amp;quot; in healthy adult volunteers.</gtr:title><gtr:parentPublicationTitle>Journal of cognitive neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4c2a8c889869049188f716ea80809693"><gtr:id>4c2a8c889869049188f716ea80809693</gtr:id><gtr:otherNames>Murphy SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0898-929X</gtr:issn><gtr:outcomeId>953169FCC83</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E33929C-1F9C-4813-BBC8-C084362BB26E</gtr:id><gtr:title>Short-term antidepressant treatment modulates amygdala response to happy faces.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66e098825713ff2a824ed36b33d241e9"><gtr:id>66e098825713ff2a824ed36b33d241e9</gtr:id><gtr:otherNames>Norbury R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>5788E72EF74</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9468DC7A-9836-4634-8D99-22AC324CD87B</gtr:id><gtr:title>Efficient ?-aminobutyric acid editing at 3T without macromolecule contamination: MEGA-SPECIAL.</gtr:title><gtr:parentPublicationTitle>NMR in biomedicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/edd8474b99dab84a174df456f80a5901"><gtr:id>edd8474b99dab84a174df456f80a5901</gtr:id><gtr:otherNames>Near J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0952-3480</gtr:issn><gtr:outcomeId>pm_13634_24_21387450</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>04A4020F-0604-4F00-8E62-6A3F41E37BC4</gtr:id><gtr:title>Fronto-limbic effective connectivity as possible predictor of antidepressant response to SSRI administration.</gtr:title><gtr:parentPublicationTitle>European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2552c1a99e362c1c7aaf8617945d3876"><gtr:id>2552c1a99e362c1c7aaf8617945d3876</gtr:id><gtr:otherNames>Vai B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0924-977X</gtr:issn><gtr:outcomeId>58ad91bd7ff651.83780339</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FA1DE598-F146-4AF7-9025-9B9FC89444F6</gtr:id><gtr:title>Serotonin transporter polymorphisms (SLC6A4 insertion/deletion and rs25531) do not affect the availability of 5-HTT to [11C] DASB binding in the living human brain.</gtr:title><gtr:parentPublicationTitle>NeuroImage</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0dfa4fe8cf2b2b2edca20658bfa7f1f6"><gtr:id>0dfa4fe8cf2b2b2edca20658bfa7f1f6</gtr:id><gtr:otherNames>Murthy NV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1053-8119</gtr:issn><gtr:outcomeId>UTFP3jsBH6S</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E525B181-2E51-4731-B5F3-E155108BE6CD</gtr:id><gtr:title>The effect of the serotonin transporter polymorphism (5-HTTLPR) on amygdala function: a meta-analysis.</gtr:title><gtr:parentPublicationTitle>Molecular psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4c2a8c889869049188f716ea80809693"><gtr:id>4c2a8c889869049188f716ea80809693</gtr:id><gtr:otherNames>Murphy SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1359-4184</gtr:issn><gtr:outcomeId>pm_13634_24_22488255</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2F6181D2-822C-426A-9B22-1018A91BE78A</gtr:id><gtr:title>Measuring endogenous changes in serotonergic neurotransmission in humans: a [11C]CUMI-101 PET challenge study.</gtr:title><gtr:parentPublicationTitle>Molecular psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f36a0b46d325daf7d58d5c21cdcf6fda"><gtr:id>f36a0b46d325daf7d58d5c21cdcf6fda</gtr:id><gtr:otherNames>Selvaraj S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1359-4184</gtr:issn><gtr:outcomeId>pm_13634_24_22665264</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>44D27427-36D7-4682-B556-21F8CA697EF7</gtr:id><gtr:title>Acute fluoxetine modulates emotional processing in young adult volunteers.</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f2066727af80b3f62b763a681af70cd6"><gtr:id>f2066727af80b3f62b763a681af70cd6</gtr:id><gtr:otherNames>Capit?o LP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn><gtr:outcomeId>56d6c656be8af7.55558324</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>988885DB-ED66-44A8-BF9D-107DDCF4958A</gtr:id><gtr:title>Oxytocin enhances processing of positive versus negative emotional information in healthy male volunteers.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e9182640a623f56707624b00a3d534b"><gtr:id>3e9182640a623f56707624b00a3d534b</gtr:id><gtr:otherNames>Di Simplicio M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>06686C01C79</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D097F9A3-DAB3-4E36-A567-F4EBD03EC1B6</gtr:id><gtr:title>Increased neural response to fear in patients recovered from depression: a 3T functional magnetic resonance imaging study.</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66e098825713ff2a824ed36b33d241e9"><gtr:id>66e098825713ff2a824ed36b33d241e9</gtr:id><gtr:otherNames>Norbury R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn><gtr:outcomeId>6861AD20846</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CDA0CAC8-FEFE-43DD-A13F-D6967D24607F</gtr:id><gtr:title>Frequency and phase drift correction of magnetic resonance spectroscopy data by spectral registration in the time domain.</gtr:title><gtr:parentPublicationTitle>Magnetic resonance in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/edd8474b99dab84a174df456f80a5901"><gtr:id>edd8474b99dab84a174df456f80a5901</gtr:id><gtr:otherNames>Near J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0740-3194</gtr:issn><gtr:outcomeId>doi_55f98498482088f8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>833BE039-FF80-40B9-A162-039ED9CB694F</gtr:id><gtr:title>Reduction in occipital cortex gamma-aminobutyric acid concentrations in medication-free recovered unipolar depressed and bipolar subjects.</gtr:title><gtr:parentPublicationTitle>Biological psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/606788fd0f3df58c3e78973256862006"><gtr:id>606788fd0f3df58c3e78973256862006</gtr:id><gtr:otherNames>Bhagwagar Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0006-3223</gtr:issn><gtr:outcomeId>A046BF516F9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FEFDF122-8F69-4DDD-B709-FB24C28CFC4D</gtr:id><gtr:title>Normal glutamate but elevated myo-inositol in anterior cingulate cortex in recovered depressed patients.</gtr:title><gtr:parentPublicationTitle>Journal of affective disorders</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/880cf52474bd701e7fe0e2f26464865f"><gtr:id>880cf52474bd701e7fe0e2f26464865f</gtr:id><gtr:otherNames>Taylor MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0165-0327</gtr:issn><gtr:outcomeId>D9E2991A5DF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>670667B1-8F90-4B40-B688-D9B0A14518A6</gtr:id><gtr:title>Why do antidepressants take so long to work? A cognitive neuropsychological model of antidepressant drug action.</gtr:title><gtr:parentPublicationTitle>The British journal of psychiatry : the journal of mental science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9714622cbdf3aade07f0e4b795152598"><gtr:id>9714622cbdf3aade07f0e4b795152598</gtr:id><gtr:otherNames>Harmer CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-1250</gtr:issn><gtr:outcomeId>56d6c35aa78194.81420945</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C9471074-1441-406E-900E-3E90C13821E1</gtr:id><gtr:title>Has psychopharmacology got a future?</gtr:title><gtr:parentPublicationTitle>The British journal of psychiatry : the journal of mental science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/657ebacd2810a554a2431b4b880d4b90"><gtr:id>657ebacd2810a554a2431b4b880d4b90</gtr:id><gtr:otherNames>Cowen PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-1250</gtr:issn><gtr:outcomeId>pm_13634_24_21525514</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6DAA6DB0-5308-46F4-B637-6DACED6D593D</gtr:id><gtr:title>Subcortical brain structure and suicidal behaviour in major depressive disorder: a meta-analysis from the ENIGMA-MDD working group.</gtr:title><gtr:parentPublicationTitle>Translational psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3940b727d7521aed617a6cf6452cd635"><gtr:id>3940b727d7521aed617a6cf6452cd635</gtr:id><gtr:otherNames>Renter?a ME</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2158-3188</gtr:issn><gtr:outcomeId>5a8add6ddd15a2.80730830</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A526BD5C-B707-454B-BAFA-7E4DB0BBFC88</gtr:id><gtr:title>Short-term NK1 receptor antagonism and emotional processing in healthy volunteers.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6aeda73005ba3b506f69f4a60f8cc0ca"><gtr:id>6aeda73005ba3b506f69f4a60f8cc0ca</gtr:id><gtr:otherNames>Pringle A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>pm_13634_24_21161182</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>43CAA2DB-A17A-4796-AA5F-EEA247A1BFDA</gtr:id><gtr:title>Cognitive mechanisms of diazepam administration: a healthy volunteer model of emotional processing.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6aeda73005ba3b506f69f4a60f8cc0ca"><gtr:id>6aeda73005ba3b506f69f4a60f8cc0ca</gtr:id><gtr:otherNames>Pringle A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>58ad91bdc961d1.03350812</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0067448A-C43D-47A4-971B-BAC0E69295F0</gtr:id><gtr:title>Early effects of mirtazapine on emotional processing.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5df8850a1f0a1e49d2c0f76d0778101d"><gtr:id>5df8850a1f0a1e49d2c0f76d0778101d</gtr:id><gtr:otherNames>Arnone D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>CA626045325</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0701421</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>3C193D18-12BD-4B15-8347-037BA623E0FF</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Mental Health</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>